Jazz Pharmaceuticals Valuation
| J7Z Stock | EUR 116.85 1.15 0.97% |
At this time, the firm appears to be undervalued. Jazz Pharmaceuticals plc retains a regular Real Value of €133.46 per share. The prevalent price of the firm is €116.85. Our model calculates the value of Jazz Pharmaceuticals plc from evaluating the firm fundamentals such as Return On Equity of -0.0056, current valuation of 13.72 B, and Return On Asset of 0.053 as well as inspecting its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Jazz Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Jazz Pharmaceuticals plc is based on 3 months time horizon. Increasing Jazz Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Jazz stock is determined by what a typical buyer is willing to pay for full or partial control of Jazz Pharmaceuticals plc. Since Jazz Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Jazz Stock. However, Jazz Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 116.85 | Real 133.46 | Hype 116.85 | Naive 121.07 |
The real value of Jazz Stock, also known as its intrinsic value, is the underlying worth of Jazz Pharmaceuticals plc Company, which is reflected in its stock price. It is based on Jazz Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Jazz Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Jazz Pharmaceuticals plc helps investors to forecast how Jazz stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Jazz Pharmaceuticals more accurately as focusing exclusively on Jazz Pharmaceuticals' fundamentals will not take into account other important factors: Jazz Pharmaceuticals Total Value Analysis
Jazz Pharmaceuticals plc is currently estimated to have takeover price of 13.72 B with market capitalization of 8.38 B, debt of 6.02 B, and cash on hands of 833.95 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Jazz Pharmaceuticals fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
13.72 B | 8.38 B | 6.02 B | 833.95 M |
Jazz Pharmaceuticals Investor Information
About 93.0% of the company shares are owned by institutional investors. The book value of Jazz Pharmaceuticals was currently reported as 43.65. The company recorded a loss per share of 0.26. Jazz Pharmaceuticals plc had not issued any dividends in recent years. Based on the key indicators related to Jazz Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Jazz Pharmaceuticals plc is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Jazz Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Jazz Pharmaceuticals has an asset utilization ratio of 25.16 percent. This implies that the Company is making €0.25 for each dollar of assets. An increasing asset utilization means that Jazz Pharmaceuticals plc is more efficient with each dollar of assets it utilizes for everyday operations.Jazz Pharmaceuticals Ownership Allocation
Jazz Pharmaceuticals plc has a total of 62.97 Million outstanding shares. The majority of Jazz Pharmaceuticals plc outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Jazz Pharmaceuticals to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Jazz Pharmaceuticals plc. Please pay attention to any change in the institutional holdings of Jazz Pharmaceuticals plc as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Jazz Pharmaceuticals Profitability Analysis
The company reported the revenue of 3.09 B. Net Loss for the year was (329.67 M) with profit before overhead, payroll, taxes, and interest of 2.88 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Jazz Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Jazz Pharmaceuticals and how it compares across the competition.
About Jazz Pharmaceuticals Valuation
The stock valuation mechanism determines Jazz Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Jazz Pharmaceuticals. We calculate exposure to Jazz Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Jazz Pharmaceuticals's related companies.Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc. Codiak BioSciences, Inc. Pfenex, Inc. and XL-protein GmbH. JAZZ PHARMACEUT operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 1460 people.
8 Steps to conduct Jazz Pharmaceuticals' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Jazz Pharmaceuticals' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Jazz Pharmaceuticals' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Jazz Pharmaceuticals' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Jazz Pharmaceuticals' revenue streams: Identify Jazz Pharmaceuticals' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Jazz Pharmaceuticals' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Jazz Pharmaceuticals' growth potential: Evaluate Jazz Pharmaceuticals' management, business model, and growth potential.
- Determine Jazz Pharmaceuticals' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Jazz Pharmaceuticals' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Jazz Stock analysis
When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |